[6] AMATO M P, PONZIANI G, SIRACUSA G, et al. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years [J]. Arch Neurol, 2001, 58(10): 1602-1606. [7]HTTPS://WWW.MSRESEARCHUPDATE.COM/POST/IS-THERE-A-NEED-F...
[6] AMATO M P, PONZIANI G, SIRACUSA G, et al. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years [J]. Arch Neurol, 2001, 58(10): 1602-1606. [7]HTTPS://WWW.MSRESEARCHUPDATE.COM/POST/IS-THERE-A-NEED-FOR-NEDA. [8] 杨红, 孙雅静, 臧卫周 等. ...
[6] AMATO M P, PONZIANI G, SIRACUSA G, et al. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years [J]. Arch Neurol, 2001, 58(10): 1602-1606. [7]HTTPS://WWW.MSRESEARCHUPDATE.COM/POST/IS-THERE-A-NEED-FOR-NEDA. [8] 杨红, 孙雅静, 臧卫周 等. ...
Stephen L HauserJohn Wiley and Sons Inc.Ann Clin Transl Neurolvon Budingen H-C, Bischof A, Eggers EL, Wang S, Bevan CJ, Cree BAC, Henry RG, Hauser SL. 2016. Onset of second- ary progressive MS after long-term rituximab therapy--A case report. Ann Clin Transl Neurol 41:...
Relapsing MS is clearly the major MS phenotype. However, 10% to 15% of MS begins with gradual worsening from onset, referred to as primary progressive MS (PPMS). The fourth and final MS clinical phenotype is secondary progressive MS (SPMS). It is believed that every relapsing patient has ...
C. neoformans infections were rare prior to the onset of the AIDS epidemic, but have now become a leading cause of morbidity and mortality in AIDS and other immunocompromised patients [84]. The prevalence of cryptococcal infections has been reported to be 5–10% among AIDS patients in the ...
When DIPL is associated with tissue injury, as in gentamicin-associated kidney injury, the di-22:6-BMP biomarker response can be correlated with the toxicity time of onset and rate of progression (from urinary DIKI biomarkers), dose response curve, and exposure effect level (Cmax and AUC). ...
The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and...
Secondary outcomes are the relationships of the CEBA profile with demographic and disease-related characteristics, such as MS subtype, age of disease onset, medication and EDSS (obtained from anamnesis or medical records), and level of societal participation (derived from the score on the Impact on...
Remove patients with no onset date 55,405 Remove patients with diagnosis date after extraction date 55,381 Remove patients with visit dates after extraction date 55,351 Remove patients with no visits 55,632 Remove patients with no EDSS measurements 51,327 Remove patients with less than 3 visits...